Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Prostate Cancer · Hot Flush

Astellas Pharma

Astellas Pharma GmbH

Astellas Pharma patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Company details
Status
Public
HQ
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
Employees
12,378
Programs
22
Drugs
52
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Astellas Pharma patents

25 pharmaceutical patents indexed for Astellas Pharma. 0 expire within 24 months.

Astellas Pharma has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

25 patents

Patent portfolio

  1. AU 2022206771

    Drug conjugates comprising antibodies against Claudin 18.2

    Expires Wed Feb 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. EP 3791896

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    Expires Tue Mar 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. LT 3254695

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    Expires Sun Dec 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. EP 3708579

    CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE

    Expires Tue Sep 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. HR P20200591

    ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)

    Expires Thu Jul 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 2020199221

    ANTIBODIES USEFUL IN CANCER DIAGNOSIS

    Expires Wed Jun 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2020095183

    COMBINAISON POUR LE TRAITEMENT DU CANCER

    Expires Wed May 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 2019076525

    THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    Expires Wed Mar 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. EP 3421496

    ANTIKÖRPER ZUR BEHANDLUNG VON CLAUDIN-6-EXPRIMIERENDEN KREBS

    Expires Tue Dec 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 2018326059

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    Expires Wed Nov 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. EP 3283521

    ARZNEIMITTELKONJUGATE MIT ANTIKÖRPERN GEGEN MIT CLAUDIN 18.2

    Expires Tue Feb 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 2018000900

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    Expires Wed Dec 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. AU 2016249784

    Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

    Expires Wed Oct 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 2016185873

    MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER

    Expires Wed Jun 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 2016159901

    DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS

    Expires Wed Jun 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. EP 3027208

    DIAGNOSE UND THERAPIE VON KREBS MIT KREBSSTAMMZELLEN

    Expires Tue Jun 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. EP 2976360

    THERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    Expires Tue Jan 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. EP 2958945

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    Expires Tue Dec 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. EP 2852409

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    Expires Tue Mar 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. EP 2847225

    ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE

    Expires Tue Mar 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. CA 3169263

    AGENTS DE TRAITEMENT DE MALADIES CANCEREUSES EXPRIMANT CLAUDINE

    Expires Wed May 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. EP 2662386

    Antikörper, die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibieren

    Expires Tue Nov 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. EP 2591003

    KREBSTHERAPIE MITTELS CLDN6-ZIELGERICHTETER ANTIKÖRPER IN VIVO

    Expires Tue May 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. AU 2011260615

    Oral dosage forms of bendamustine

    Expires Wed Jan 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. AU 2011260614

    Oral dosage forms of bendamustine and therapeutic use thereof

    Expires Wed Jan 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Astellas Pharma have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Astellas Pharma patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.